SEARCH

SEARCH BY CITATION

REFERENCES

  • Antonarakis SE, the Nomenclature Working Group. 1998. Recommendations for a nomenclature system for human gene mutations. Hum Mut 11:13.
  • Armstrong MD, Tyler FH. 1955. Studies on phenylketonuria. I. Restriction phenylalanine intake in phenylketonuria. J Clin Invest 34:565.
  • Barbujani G, Goldstein DB. 2004. Africans and Asian abroad: genetic diversity in Europe. Annu Rev Genomics Hum Genet 5:119150.
  • Barkai N, Leiber S. 1997. Robustness in simple biochemical networks. Nature 387:913917.
  • Bearn AG. 1993. Archibald Garrod and the individuality of man. Oxford: Clarendon Press. pp xvi, 227.
  • Bernegger C, Blau N. 2002. High frequency of tetrahydrobiopterin-responsiveness among hyperphenylalaninemias: A study of 1,919 patients observed from 1988 to 2002. Mol Genet Metab 77:304313.
  • Betts S, Haase-Petingell C, King J. 1997. Mutational effects on inclusion body formation. Adv Protein Chem 50:243264.
  • Bickel H, Gerrard J, Hickmans EM. 1954. Influence of phenylalanine intake on the chemistry and behaviour of a phenylketonuric child. Acta Paediatr 43:64. [Swedish]
  • Bjorgo E, Knappskog PM, Martinez A, Stevens RC, Flatmark T. 1998. Partial characterization and three-dimensional-structural localizaton of eight mutations in exon 7 of the human phenylalanine hydroxylase gene associated with phenylketonuria. Eur J Biochem 257:110.
  • Blau N. 2003. Disorders of tetrahydrobiopterin and related biogenic amines. In: ScriverCR, BeaudetAL, SlySW, ValleD, associate editors. ChildsB, KinzlerKW, VogelsteinB, editors. The metabolic and molecular bases of inherited disease. New York: McGraw Hill. [Available at: http://genetics.accessmedicine.com/server-java/Arknoid/amed/mmbid/co_chapters/ch078/ch078_p01.html. Part Eight: Amino Acids, chapter78.]
  • Byck S, Morgan K, Tyfield L, Dworniczak B, Scriver CR. 1994. Evidence for origin, by recurrent mutation, of the phenylalanine hydroxylase R408W mutation on two haplotypes in European and Quebec populations. Hum Molec Genet 3:16751677.
  • Byck S, Tyfield L, Carter K, Scriver CR. 1997. Prediction of multiple hypermutable codons in the human PAH gene: Codon 280 contains recurrent mutations in Quebec and other populations. Hum Mut 9:316321.
  • Campeau P, Mitchell JJ, Scriver CR. 2006. An analysis of treatment efficacy in inborn errors of metabolism [Abstract]. J Inherit Metab Dis 29(Suppl 1):64.
  • Carter KC, Byck S, Waters PJ, Richards B, Nowacki PM, Laframboise R, Lambert M, Treacy E, Scriver CR. 1998. Mutation at the phenylalanine hydroxylase gene (PAH) and its use to document population genetic variation: the Quebec experience. Eur J Hum Genet 6:6170.
  • Cavalli-Sforza LL, Piazza A. 1993. Human genomic diversity in Europe: a summary of recent research and prospects for the future. Eur J Hum Genet 1:318.
  • Cavalli-Sforza LL, Menozzi P, Piazza A. 1994. The history and geography of human genes. Princeton, New Jersey: Princeton Univ Press. pp xi, 541, maps 1–518.
  • Cavalli-Sforza LL. 1998. The DNA revolution in population genetics. Trends Genet 14:6065.
  • Chakraborty R, Lidsky AS, Daiger SP, Guttler F, Sullivan S, DiLella AG, Woo SL. 1987. Polymorphic DNA haplotypes at the human phenylalanine hydroxylase locus and their relationship with phenylketonuria. Hum Genet 76:4046.
  • Chen L, Woo SLC. 2005. Complete and persistent phenotypic correction of phenylketonuria in mice by site-specific genome integration of murine phenylalanine hydroxylase cDNA. Proc Nat Acad Sci USA 102:1558115586.
  • Claustres M, Horaitis O, Vanevski M, Cotton RGH. 2002. Time for a unified system of mutation description and reporting: A review of locus-specific mutation databases. Genome Res 12:680688.
  • Cockburn F, Clark BJ. 1996. Recommendations for protein and amino acid intake in phenylketonuric patients. Eur J Pediatr 155:S1:125129.
  • Costa T, Scriver CR, Childs B. 1985. The effect of Mendelian disease on human health: A measurement. Amer J Med Genet 21:231242.
  • Crosby AW. 1986. Ecological Imperialism. The biological expansion of Europe 900–1900. Cambridge UK: Cambridge Univ. Press. 368p.
  • Daiger SP, Chakraborty R, Reed L, Fekete G, Schuler D, Berenssi G, Nasz I, Brdicka R, Kamaryt J, Pijackova A, Moore S, Sullivan S, Woo SLC. 1989a. Polymorphic DNA haplotypes at the phenylalanine hydroxylase (PAH) locus in European families with phenylketonuria (PKU). Am J Hum Genet 45:310318.
  • Daiger SP, Reed L, Huang S-Z, Zeng Y-T, Wang T, Lo WHY, Okano Y, Hase Y, Fukuda Y, Oura T, Tada K, Woo SLC. 1989b. Polymorphic DNA haplotypes at the phenylalanine hydroxylase (PAH) locus in Asian families with phenylketonuria (PKU). Am J Med Genet 45:319324.
  • Danks DM, Bartholomé K, Clayton BE, Curtius H, Grobe H, Kaufman S, Leeming R, Pfleiderer W, Rembold H, Rey F. 1978. Malignant hyperphenylalaninemaemia—current status (June 1977). J Inher Metab Dis 1:4953.
  • Degioanni A, Darlu P. 1994. Analysis of the molecular variance at the phenylalanine hydroxylase (PAH) locus. Eur J Hum Genet 2:166176.
  • den Dunnen JT, Antonarakis SE. 2000. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mut 15:712.
  • Dent CE. 1957. Relation of biochemical abnormality to development of mental defect in phenylketonuria. Discussion to paper by Armstrong, M.D. In: Report of 23rd Ross Pediatric Research Conference. Etiological factors in mental retardation. Columbus, Ohio: Ross Laboratories. pp 2223.
  • Desviat LR, Perez B, Gamez S, Sanchez A, Garcia MJ, Martinez-Pardo M, Marchante C, Boveda D, Baldellou A, Arena J, Sanjurjo P, Fernandez A, Cabello ML, Ugarte M. 1999. Genetic and phenotypic aspects of phenylalanine hydroxylase deficiency in Spain: molecular survey by regions. Eur J Hum Genet 7:386392.
  • Di Silvestre D, Koch R, Groffen J. 1991. Different clinical manifestations in three siblings with identical phenylalanine hydroxylase genes. Am J Hum Genet 48:10141016.
  • DiLella AG, Marvit J, Lidsky AS, Guttler F, Woo SLC. 1986. Tight linkage between a splicing mutation and a specific DNA haplotype in phenylketonuria. Nature 322:799803.
  • DiLella AG, Marvit J, Brayton K, Woo SLC. 1987. An amino-acid substitution involved in phenylketonuria is in linkage disequilibrium with DNA haplotype 2. Nature 327:333338.
  • Ding Z, Harding CO, Thony B. 2004. State-of-the-art 2003 on PKU gene therapy. Mol Genet Metab 81:38.
  • Dipple KM, McCabe ERB. 2000a. Modifier genes convert “simple” Mendelian disorders to complex traits. Mol Genet Metab 71:4350.
  • Dipple KM, McCabe ERB. 2000b. Phenotypes of patients with “simple” Mendelian disorders are complex traits: thresholds, modifiers, and systems dynamics. Am J Hum Genet 66:17291735.
  • Dipple KM, Phelan JK, McCabe ERB. 2001. Minireview: consequences of complexity within biological networks: Robustness and health or vulnerability and disease. Mol Genet Metab 74:4550.
  • Donlon J, Levy H, Scriver CR. 2004. Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. In: ScriverCR, BeaudetAL, SlySW, ValleD, associate editors. ChildsB, KinzlerKW, VogelsteinB, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill. [Available at http://genetics.accessmedicine.com/server-java/Arknoid/amed/mmbid/co_chapters/ch077/ch077_p01.html Part Eight: Amino Acids, Chapter 77. Last accessed 20 March 2007]
  • Eiken HG, Knappskog PM, Apold J, Flatmark T. 1996. PKU mutation G46S associated with increased aggregation and degradation of the phenylalanine hydroxylase enzyme. Hum Mutat 7:228238.
  • Eisensmith RC, Goltsov AA, O'Neill C, Tyfield LA, Schwartz EI, Kuzmin AI, Baranovskaya SS, Tsukerman GL, Treacy E, Scriver CR, Güttler F, Guldberg P, Eiken HG, Apold J, Svensson E, Naughten E, Cahalane SF, Croke DT, Cockburn F, Woo SLC. 1995. Recurrence of the R408W mutation in the phenylalanine hydroxylase locus in Europeans. Am J Hum Genet 56:278286.
  • Erlandsen H, Stevens RC. 1999. The structural basis of phenylketonuria. Mol Genet Metab 68:103125.
  • Erlandsen H, Pey AL, Gamez A, Perez B, Desviat LR, Aguado C, Koch R, Surendran S, Tyring S, Matalon R, Scriver CR, Ugarte M, Martinez A, Stevens RC. 2004. Correction of kinetic and stability defects by the tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. Proc Nat Acad Sci USA 101:1690316908.
  • Falush D, Wirth T, Linz B, Pritchard JK, Stephens M, Kidd M, Blaser MJ, Graham DY, Vacher S, Perea-Perez GI, Yamaoka Y, Megraud F, Otto K, Reichard U, Katzowitsch E, Wang X, Achtman M, Suerbaum S. 2003. Traces of human migrations in Helicobacter pylori populations. Science 299:15821585.
  • Fay JC, Wu CI. 2000. Hitchhiking under positive Darwinian selection. Genetics 155:14051413.
  • Fölling A. 1934. Uber Ausscheidung von Phenylbrenztraubensaure in den Harn als Stoffwechselanomalie in Verbindung mit Imbezillitat. Hoppe Seylers Z Physiol Chem 277:169176. [German]
  • Garrigan D, Mobasher Z, Kingan SB, Wilder JA, Hammer MF. 2005. Deep haplotype divergence and long-range linkage disequilibrium at Xp21.1 provide evidence that humans descend from a structured ancestral population. Genetics 170:18491856.
  • Garrod AE. 1902. The incidence of alkaptonuria. A study in chemical individuality. Lancet 2:16161620.
  • Garrod AE. 1908. Inborn errors of metabolism. The Croonian Lectures delivered before the Royal College of Physicians in London in June 1908. London. Henry Frowde; Hodder and Stoughton. Oxford University Press. Reprinted in Harris H. 1963. Garrod's Inborn Errors of Metabolism. Reprinted with a supplement. Oxford Monographs on Medical Genetics, London, Oxford University Press. pp ix, 207.
  • Garrod AE. 1924. The debt of science to medicine. Br Med J 2:747752.
  • Giardine B, Riemer C, Hefferon T, Thomas D, Shu F, Zielenski J, Sang Y, Elnitski L, Cutting G, Trumbower H, Kern A, Kuhn R, Patrinos GP, Hughes J, Higgs D, Chui D, Scriver C, Phommarinh M, Patnaik SK, Blumenfeld O, Gottlieb B, Vihinen M, Valiaho J, Kent J, Miller J, Hardison RC. 2007. PhenCode: connecting ENCODE data with mutations and phenotype. Hum Mutat 28:554562.
  • Glazier AM, Nadeau JH, Altman TJ. 2002. Finding genes that underlie complex traits. Science 298:23452349.
  • Gold RJM, Maag UR, Neal JL, Scriver CR. 1974. The use of biochemical data in screening for mutant alleles and in genetic counselling. Ann Hum Genet 37:315326.
  • Gu X, Wang Z. 2004. [Screening for phenylketonuria and congenital hypothyroidism in 5.8 million neonates in China]. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine] 38:99102. [Chinese]
  • Guldberg P, Zschocke J, Dagbjartsson A, Friis Henriksen K, Güttler F. 1997. A molecular survey of phenylketonuria in Iceland: identification of a founding mutation and evidence of predominant Norse settlement. Eur J Hum Genet 5:376381.
  • Guldberg P, Rey F, Zschocke J, Romano C, Francois B, Michiels L, Ullrich K, Hoffman GF, Burgard P, Schmidt H, Meli C, Riva E, Dianzani I, Ponzone A, Rey J, Güttler F. 1998. A European multicenter study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype. Am J Hum Genet 63:7179.
  • Guthrie R, Susi A. 1963. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 32:318343.
  • Güttler F, Guldberg P, Henriksen KF. 1993. Mutation genotype of mentally retarded patients with phenylketonuria. Dev Brain Dysfunct 6:9296.
  • Hanley WB, Platt LD, Bachman RP, Buist N, Geraghty MT, Isaacs J, O'Flynn ME, Rhead WJ, Seidlitz G, Tishler B. 1999. Undiagnosed maternal phenylketonuria: the need for prenatal selective screening or case finding. Am J Obstet Gynecol 180:986994.
  • Hardelid P, Cortina-Borja M, Munro A, Joans H, Cleary M, Champion M, Foo Y, Scriver CR, Dezateux C. Did PKU in Caucasians and Asian Orientals arise after the out-of-Africa range expansion? Ann Hum Genet (in press).
  • Harding CO, Ding Z, Thöny B. 2006. Gene and cell therapies for phenylketonuria (PKU). In: BlauN, editor. PKU and BH4—advances in phenylketonuria and tetrahydrobiopterin. Heilbronn: SPS Verlagsgesellschaft. p 321349.
  • Hartman JL, Garvik B, Hartwell L. 2001. Principles for the buffering of genetic variation. Science 291:10011004.
  • Hartwell LH, Hopfield JJ, Leiber S, Murray AW. 1999. From molecular to modular cell biology. Nature 402:C47C52.
  • Hayes A, Costa T, Scriver CR, Childs B. 1985. The effect of Mendelian disease on human health. II. Response to treatment. Amer J Med Genet 21:243255.
  • Helgason A, Siguröardóttir S, Gulcher JR, Ward R, Stefansson K. 2000. mtDNA and the origin of the Icelanders: Decifering signals of recent population history. Am J Hum Genet 66:9991016.
  • Hertzberg M, Jahromi K, Ferguson V, Dahl HHM, Mercer J, Mickleson KNP, Trent RJ. 1989. Phenylalanine hydroxylase gene haplotypes in Polynesians: evolutionary origins and absence of alleles associated with severe phenylketonuria. Am J Hum Genet 44:382387.
  • Hoang L, Byck S, Prevost L, Scriver CR, curators. 1996. PAH Mutation Analysis Consortium Database: a database for disease-producing and other allelic variation in the human PAH locus. Nucleic Acids Res 24:127131.
  • Hofman KJ, Steel G, Kazazian HH, Valle D. 1991. Phenylketonuria in U.S. Blacks: molecular analysis of the phenylalanine hydroxylase gene. Am J Hum Genet 48:791798.
  • Jeong H, Tombor B, Albert R, Otlval ZN, Barabasi AL. 2000. The large-scale organization of metabolic networks. Nature 407:651654.
  • Jervis GA. 1953. Phenylpyruvic oligophrenia: deficiency of phenylalanine oxidizing system. Proc Soc Exp Biol Med 82:514.
  • John SWM, Rozen R, Scriver CR, Laframboise R, Laberge C. 1990. Recurrent mutation, gene conversion, or recombination at the human phenylalanine hydroxylase locus: evidence in French-Canadians and a catalog of mutations. Am J Hum Genet 46:970974.
  • Kacser H, Burns JA. 1981. The molecular basis of dominance. Genetics 97:639666.
  • Kaufman S. 1963. The structure of phenylalanine hydroxylation cofactor. Proc Natl Acad Sci USA 50:1085.
  • Kayaalp E, Treacy E, Waters PJ, Byck S, Nowacki P, Scriver CR. 1997. Human phenylalanine hydroxylase mutations and hyperphenylalaninemia phenotypes: a metanalysis of genotype-phenotype correlations. Am J Hum Genet 61:13091317.
  • Kidd JR, Kidd KK. 2005. The population genetics of PAH. Online. Supplement to Chapter 77. The hyperphenylalaninemias. DonlonJ, LevyH, ScriverCR. In: ScriverCR, BeaudetAL, SlySW, ValleD, associate editors ChildsB, KinzlerKW, VogelsteinB, editors. The metabolic and molecular bases of inherited disease. Online. New York: McGraw-Hill.
  • Kidd KK. 1987. Phenylketonuria. Population genetics of a disease. Nature 327:282283.
  • Kidd KK, Morar B, Castiglioni CM, Zhao H, Pakstis AJ, Speed WC, Bonne-Tamir B, Lu RB, Goldman D, Lee C, Nam YS, Grandy DK, Jenkins T, Kidd JR. 1998. A global survey of haplotype frequencies and linkage disequilibrium at the DRD2 locus. Hum Genet 103:211227.
  • Kidd JR, Pakstis AJ, Zhao H, Lu R-B, Okonofua FE, Odunsi A, Grigorenko E, Bonne-Tamir B, Friedlaender J, Schulz LO, Parnas J, Kidd KK. 2000. Haplotypes and linkage disequilibrium at the phenylalanine hydroxylase locus, PAH, in a global representation of populations. Am J Hum Genet 66:18821899.
  • Kirkman HN. 1992. Projections of a rebound in frequency of mental retardation from phenylketonuria. Appl Res Ment Retard 3:319328.
  • Kirschner M, Gerhart J, Mitchison T. 2000. Molecular “vitalism”. Cell 100:7988.
  • Knox WE. 1970. Retrospective study of phenylketonuria: relation of phenyl-pyruvate excretion to plasma phenylalanine. Unpublished private PKU Newsletter #2.
  • Koch R, Fishler K, Azen C, Guldberg P, Güttler F. 1997. The relationship of genotype to phenotype in phenylalanine hydroxylase deficiency. Biochem Mol Med 60:92101.
  • Konecki DS, Wang Y, Trefz FK, Lichter-Konecki U, Woo SLC. 1992. Structural characterization of the 5′ region of the human phenylalanine hydroxylase gene. Biochemistry 31:83638368.
  • Kozak L, Hrabincova E, Kintr J, Horky O, Zapletalova P, Blahakova I, Mejstrik P, Prochazkova D. 2006. Identification and characterization of large deletions in the phenylalanine hydroxylase (PAH) gene by MLPA: evidence for both homologous and non-homologous mechanisms of rearrangement. Mol Genet Metab 89:300309.
  • Krawczak M, Zschocke J. 2003. A role for overdominant selection in phenylketonuria? Evidence from molecular data. Hum Mutat 21:394397.
  • Kuhn TS. 1970. The structure of scientific revolutions. Chicago: University of Chicago Press. pp xii, 210.
  • Kure S, Hou D-C, Ohura T, Iwamoto H, Suzuki S, Sugiyama N, Sakamoto O, Fugii K, Matsubara Y, Narisawa K. 1999. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J Pediatr 135:375378.
  • Kure S, Sato K, Fujii K, Aoki Y, Suzuki Y, Kato S, Matsubara Y. 2004. Wild-type phenylalanine hydroxylase activity is enhanced by tetrahydrobiopterin supplementation in vivo: an implication for therapeutic basis of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Mol Genet Metab 83:150156.
  • Kwok SCM, Ledley FD, DiLella AG, Robson KJH, Woo SLC. 1985. Nucleotide sequence of a full-length complementary DNA clone and amino acid sequence of human phenylalanine hydroxylase. Biochemistry 24:556561.
  • Lander ES, Schork NJ. 1994. Genetic dissection of complex traits. Science 265:20372048.
  • Langenbeck U, Lukas HD, Mench-Hoinowski A, Stenzig KP, Lane JD. 1988. Correlative study of mental and biochemical phenotypes in never treated patients with classic phenylketonuria. Brain Dysfunction 1:103110.
  • Ledley FD, Grenett HE, DiLella AG, Kwok SCM, Woo SLC. 1985. Gene transfer and gene expression of human phenylalanine hydroxylase. Science 228:7779.
  • Lee DH, Koo SK, Lee K-S, Yeon Y-J, Oh H-J, Kim S-W, Lee S-J, Kim S-S, Lee J-E, Jo I, Jung S-C. 2004. The molecular basis of phenylketonuria in Koreans. J Hum Genet 49:617621.
  • Lenke RR, Levy HL. 1980. Maternal phenylketonuria and hyperphenylalaninemia. An international survey of untreated and treated pregnancies. New Engl J Med 303:12021208.
  • Levy HL, Guldberg P, Guttler F, Hanley WB, Matalon R, Rouse BM, Trefz F, Azen C, Allred EN, De La Cruz F, Koch R. 2001. Congenital heart disease in maternal phenylketonuria. Report from the maternal PKU collaborative study. Pediat Res 49:636642.
  • Lichter-Konecki U, Hipke CM, Konecki D. 1999. Human phenylalanine hydroxylase gene expression in kidney and other nonhepatic tissues. Mol Genet Metab 67:308316.
  • Lidsky AS, Ledley FD, DiLella AG, Kwok SCM, Daiger SP, Robson KJH, Woo SLC. 1985. Extensive restriction site polymorphism at the human phenylalanine hydroxylase locus and application in prenatal diagnosis of phenylketonuria. Am J Hum Genet 37:619634.
  • Matalon R, Michals-Matalon K, Bhatia G, Grechanina E, Novikov P, McDonald JD, Grady J, Tyring SK, Guttler F. 2006. Large neutral amino acids in the treatment of phenylketonuria (PKU). J Inherit Metab Dis 29:732738.
  • Maurer SM, Firestone RB, Scriver CR. 2000. Science's neglected legacy. Nature 405:117120.
  • McAdam HH, Arkin A. 1999. It's a noisy business Genetic regulation at the nanomolar scale. Trends Genet 15:6569.
  • McDonald JD, Andriolo M, Cali F, Mirisola M, Puglesi-Allegra S, Romano V, Sarkissian CN, Smith CB. 2002. The phenylketonuria mouse model: a meeting review. Mol Genet Metab 76:256261.
  • McVean G, Spencer CCA, Chaix R. 2005. Perspectives on human genetic variation from the HapMap project. PLoS Genetics 1:04130418.
  • Medical Research Council (UK). 1993. Phenylketonuria due to phenylalanine hydroxylase deficiency: an unfolding story. BMJ 306:115119.
  • Mitchell J, Scriver C (updated March 2007) Phenylalanine Hydroxylase Deficiency in: GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Copyright, University of Washington, Seattle. 1997–2007. Available at http://www.genetests.org.
  • Moats RA, Scadeng M, Nelson MD Jr. 1999. MR Imaging and spectroscopy in PKU. Ment Retard Dev Disabil Res Rev 5:132135.
  • Moller HE, Weglage J, Widermann D, Ullrich K. 1998. Blood-brain barrier phenylalanine transport and individual vulnerability in phenylketonuria. J Cereb Blood Flow Metab 18:11841191.
  • Møller LB, Paulsen M, Koch R, Moats R, Guldberg P, Güttler F. 2005. Inter-individual variation in brain phenylalanine concentration in patients with PKU is not caused by genetic variation in the 4F2hc/LAT1 complex. Mol Genet Metab 86:S119S123.
  • Mountain JL, Cavalli-Sforza LL. 1997. Multilocus genotypes, a tree of individuals, and human evolutionary history. Am J Hum Genet 61:705718.
  • Muntau AC, Roschinger W, Habich M, Demmelmair HH, Hoffmann B, Sommhoff CP, Roscher AA. 2002. Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. N Engl J Med 347:21222132.
  • Murphy BC, Scriver CR, Singh SM. 2006. CpG methylation accounts for a recurrent mutation (c.1222C>T) in the human PAH gene. Hum Mutat 27:975.
    Direct Link:
  • Nadeau JH, Topol EJ. 2006. The genetics of health. Nat Genet 38:10951098.
  • National Academy of Sciences. Committee for the Study of Inborn Errors of Metabolism [DoMSAoLS]. 1975. Genetic screening: programs, principles, and research. Washington, DC: National Academy of Sciences.
  • National Institutes of Health Consensus Development Panel. 2001. National Institutes of Health Consensus Development Conference statement: phenylketonuria: screening and management. 2000. Pediatrics 108:972982.
  • Nayman R, Thomson E, Scriver CR, Clow CL. 1979. Observations on the composition of milk-substitute products for treatment of inborn errors of amino acid metabolism. Comparisons with human milk. Am J Clin Nutr 32:1279.
  • Netzer WJ, Hartl FU. 1998. Protein folding in the cytosol: chaperonin-dependent and -independent mechanisms. Trends Biochem Sci 23:6873.
  • Nowacki PM, Byck S, Prevost L, Scriver CR. 1998. PAH Mutation Analysis Consortium Database: 1997. Prototype for relational locus-specific mutation databases. Nucleic Acids Res 26:220225.
  • Okano Y, Eisensmith RC, Guttler F, Lichter-Konecki U, Konecki DS, Trefz FK, Dasovich M, Wang T, Henriksen K, Lou H, Woo SLC. 1991. Molecular basis of phenotypic heterogeneity in phenylketonuria. N Engl J Med 324:12321238.
  • Okano Y, Hase Y, Lee D-H, Furuyama J-I, Shintaku H, Oura T, Isshiki G. 1992. Frequency and distribution of phenylketonuric mutations in Orientals. Hum Mutat 1:216220.
  • Olby R. 1974. The path to the double helix. Seattle: University of Washington Press. pp 123133.
  • Oltvai ZN, Barabasi AL. 2002. Life's complexity pyramid. Science 298:763764.
  • Penrose LS. 1935. Inheritance of phenylpyruvic amentia (phenylketonuria). Lancet 2:192194.
  • Penrose LS, Quastel JH. 1937. Metabolic studies in phenylketonuria. Biochem J 31:266271.
  • Penrose LS. 1998. Phenylketonuria. A problem in eugenics. Inaugural lecture delivered at University College on 21 January 1946. Reprinted with permission from The Lancet, 29 June, 1946. pp 949–953. Ann Hum Genet 62:193202.
  • Pietz J, Kries R, Rupp A, Mayatepek E, Rating D, Boesch C, Bremer HJ. 1999. Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Invest 103:11691178.
  • Ramus SJ, Forrest SM, Pitt DB, Saleeba JA, Cotton RGH. 1993. Comparison of genotype and intellectual phenotype in untreated PKU patients. J Med Genet 30:401405.
  • Rosenblatt D, Scriver CR. 1968. Heterogeneity in genetic control of phenylalanine metabolism in man. Nature 218:677678.
  • Salter M, Knowles RG, Pogson CI. 1986. Quantification of the importance of individual steps in the control of aromatic amino acid metabolism. Biochem J 234:635647.
  • Sarkissian CN, Shao Z, Blain F, Peevers R, Su H, Heft R, Chang TM, Scriver CR. 1999. A different approach to treatment of phenylketonuria: Phenylalanine degradation with recombinant phenylalanine ammonia lyase. Proc Natl Acad Sci USA 96:23392344.
  • Sarkissian CN, Boulais DM, McDonald JD, Scriver CR. 2000. A heteroallelic mutant mouse model: a new orthologue for human hyperphenylalaninemia. Mol Genet Metab 69:188194.
  • Sarkissian CN, Gamez A. 2005. Phenylalanine ammonia lyase, enzyme substitution therapy for phenylketonuria, where are we now? Mol Genet Metab 86:S22S26.
  • Sarkissian CN. 2006. Enzyme therapy for PKU. In: BlauN, editor. PKU and BH4—advances in phenylketonuria and tetrahydrobiopterin. Heilbronn: SPS Verlagsgesellschaft mbH. p 350369.
  • Satta Y, Takahata N. 2004. The distribution of the ancestral haplotype in finite stepping-stone models with population expansion. Mol Ecol 13:877886.
  • Scherer SE, Muzny DM, Buhay CJ, Chen R, Cree A, Ding Y, Dugan-Rocha S, Gill R, Gunaratne P, Harris RA, Hawes AC, Hernandez J, Hodgson AV, Hume J, Jackson A, Khan ZM, Kovar-Smith C, Lewis LR, Lozado RJ, Metzker ML, and 55 additional authors. 2006. The finished DNA sequence of human chromosome 12. Nature 440:346351.
  • Scriver CR. 1967. Treatment in medical genetics. In: CrowJF, NeelJV, editors. Proceedings of the Third International Congress of Human Genetics. Baltimore: The Johns Hopkins Press. p 4556.
  • Scriver CR. 1971. Mutants: consumers with special needs. Nutr Rev 29:155.
    Direct Link:
  • Scriver CR, Rosenberg LE. 1973. Amino acid metabolism and its disorders. Philadelphia: W.B. Saunders. Chapter 3, pp 3960.
  • Scriver CR, Clow CL. 1980a. Epitome of human biochemical genetics. Part I. New Engl J Med 303:1336.
  • Scriver CR, Clow CL. 1980b. Phenylketonuria: epitome of human biochemical genetics. Part II. New Engl J Med 303:1394.
  • Scriver CR, Gregory DM, Sovetts D, Tissenbaum G. 1985. Normal plasma free amino acid values in adults: The influence of some common physiological variables. Metabolism 34:868873.
  • Scriver CR. 1991. Phenylketonuria—genotypes and phenotypes. N Engl J Med 324:12801281.
  • Scriver CR, John SMW, Rozen R, Eisensmith R, Woo SLC. 1993. Associations between populations, phenylketonuria mutations and RFLP haplotypes at the phenylalanine hydroxylase locus: an overview. Dev Brain Dysfunct 6:1125.
  • Scriver CR, Byck S, Prevost L, Hoang L, PAH Mutation Analysis Consortium. 1996. The phenylalanine hydroxylase locus: a marker for the history of phenylketonuria and human genetic diversity. In: ChadwickD, CardewG, editors. Weiss KM, chair. Variation in the human genome. Chichester: John Wiley and Sons. p 7396.
  • Scriver CR, Waters PJ. 1999. Monogenic traits are not simple. Lessons from phenylketonuria. Trends Genet 15:267272.
  • Scriver CR, Nowacki PM, Lehvaslaiho H, the Working Group. 2000a. Guidelines and recommendations for content, structure, and deployment of mutation databases: II. Journey in progress. Hum Mutat 15:1315.
  • Scriver CR, Waters PJ, Sarkissian C, Ryan S, Prevost L, Cote D, Novak J, Teebi S, Nowacki PM. 2000b. PAHdb: a locus-specific knowledgebase. Hum Mutat 15:99104.
  • Scriver CR. 2001. Human genetics: lessons from Quebec population(s). Annu Rev Genomics Hum Genet 2:69101.
  • Scriver CR. 2002. Why mutation analysis does not always predict clinical consequences: explanations in the era of genomics. J Pediatr 140:502506.
  • Scriver CR, Hurtubise M, Konecki D, Phommarinh M, Prevost L, Erlandsen H, Stevens R, Waters PJ, Ryan S, McDonald D, Sarkissian C. 2003. PAHdb 2003: what a locus-specific knowledgebase can do. Hum Mutat 21:333344.
  • Scriver CR. 2004. After the genome—the phenome? J Inher Metab Dis 27:305317.
  • Scriver CR. 2006. Homeostasis, complexity, and monogenic phenotypes: the view from phenylketonuria. Supplement to Part Eight, Amino Acids, Chapter 77. In: ScriverCR, BeaudetA, SlyWS, ValleD, associate editors; ChildsB, KinzlerKW, VogelsteinB, editors. Metabolic and molecular bases of inherited disease. Online. New York: McGraw-Hill. p 14.
  • Scriver CR, Hardelid P, Cortina-Borja M, Munro A, Jones H, Foo Y, Cleary M, Champion M, Dezateux C. 2006. Did phenylketonuria (PKU) arise after the Out-of-Africa migration? Am J Hum Genet Abstract Edition, p 196. Abst. No. 995.
  • Shedlovsky A, McDonald JD, Symula D, Dove WF. 1993. Mouse models of human phenylketonuria. Genetics 134:12051210.
  • Smith I. 1994. Treatment of phenylalanine hydroxylase deficiency. Acta Paediatr Suppl 407:6065.
  • Song F, Qu Y, Zhang T, Jin Y, Wang H, Zheng X. 2005. Phenylketonuria mutations in Northern China. Mol Genet Metab 86:S107S118.
  • Spaapen JM, Rubio-Gozalbo ME. 2003. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency, state-of-the-art. Mol Genet Metab 78:9399.
  • Summers KM. 1996. Relationship between genotype and phenotype in monogenic diseases: Relevance to polygenic diseases. Hum Mutat 7:283293.
  • Tajima F. 1989. Statistical method for testing the neutral mutation hypothesis by DNA polymorphism. Genetics 123:585595.
  • Tessari P, Deferrari G, Robaudo C, Vettore M, Pastorino N, De Biasi L, Garibotto G. 1999. Phenylalanine hydroxylation across the kidney in humans. Kidney Int 56:21682172.
  • Thöny B, Blau N. 2006. Mutations in the BH4-metabolozing genes GTP cyclohydrolase 1,6-pyruvoyl-tetrahydroptin synthase, sepiapterin reductase, carbinolamine-4a-dehydratase, and dihydropteridine reductase. Hum Mutat 27:870878.
  • Tighe O, Dunican D, O'Neill C, Bertorelle G, Beattie D, Graham C, Zschocke J, Cali F, Romano V, Hrabincova E, Kozak L, Nechyporenko M, Livshits L, Guldberg P, Jurkowska M, Zekanowski C, Perez B, Ruiz Desviat L, Ugarte M, Kucinskas V, Knappskog P, Treacy E, Naughten E, Tyfield L, Byck S, Scriver CR, Mayne PD, Croke DT. 2003. Genetic diversity within the R408W Phenylketonuria mutation lineages in Europe. Hum Mutat 21:387393.
  • Tishkoff SA, Dietzsch E, Speed W, Pakstis AJ, Kidd JR, Cheung K, Bonne-Tamir B, Santachiara-Benerecetti AS, Moral P, Krings M. 1996. Global patterns of linkage disequilibrium at the CD4 locus and modern human origins. Science 271:13801387.
  • Tishkoff SA, Goldman A, Calafell F, Speed WC, Deinard AS, Bonne-Tamir B, Kidd JR, Pakstis AJ, Jenkins T, Kidd KK. 1998. A global haplotype analysis of the myotonic dystrophy: Implications for the evolution of modern humans and for the origin of myotonic dystrophy mutations. Am J Hum Genet 62:13891402.
  • Treacy E, Childs B, Scriver CR. 1995. Response to treatment in hereditary metabolic disease: 1993 survey and 10-year comparison. Am J Hum Genet 56:359367.
  • Treacy E, Pitt JJ, Seller J, Thompson GN, Ramus S, Cotton RGH. 1996. In vivo disposal of phenylalanine in phenylketonuria: a study of two siblings. J Inher Metab Dis 19:595602.
  • Treacy EP, Delente JJ, Elkas G, Carter K, Lambert M, Waters P, Scriver CR. 1997. Analysis of phenylalanine hydroxylase genotypes and hyperphenylalaninemia phenotypes using L-[1-13C] phenylalanine oxidation rates in vivo: a pilot study. Pediatr Res 42:430435.
  • Treacy EP, Valle D, Scriver CR. 2001. Treatment of genetic disease. In: ScriverCR, BeaudetAL, SlySW, ValleD, associate editors; ChildsB, KinzlerKW, VogelsteinB, editors. The metabolic and molecular bases of inherited disease. New York: McGraw Hill Book Co. p 175191.
  • Trefz FK, Burgard P, König T, Goebel-Schreiner B, Lichter-Konecki U, Konecki D, Schmidt E, Schmidt H, Bickel H. 1993. Genotype-phenotype correlations in phenylketonuria. Clin Chim Acta 217:1521.
  • Vajro P, Strisciuglio P, Houssin D, Huault G, Laurent J, Alvarez F, Bernard O. 1993. Correction of phenylketonuria after liver transplantation in a child with cirrhosis. N Engl J Med 329:363.
  • van Baal S, Kaimakis P, Phommarinh M, Koumbi D, Cuppens H, Riccardino F, Macek M Jr, Scriver CR, Patrinos GP. 2007. FINDbase: a relational database recording frequencies of genetic defects leading to inherited disorders worldwide. Nucleic Acids Res 35(Database issue):D690D695.
  • Wang T, Okano Y, Eisensmith RC, Harvey ML, Lo WHY, Huang SZ, Zeng TT, Yuan LF, Furuyama JI, Oura T, Sommer SS, Woo SLC. 1991a. Founder effect of a prevalent phenylketonuria mutation in the Oriental population. Proc Natl Acad Sci USA 88:21462150.
  • Wang T, Okano Y, Eisensmith RC, Lo WHY, Huang S-Z, Zeng Y-T, Woo LC. 1991b. Identification of a novel phenylketonuria (PKU) mutation in the Chinese: further evidence for multiple origins of PKU in Asia. Am J Hum Genet 48:628630.
  • Wang Y, DeMayo JL, Hahn TM, Finegold MJ, Konecki DS, Lichter-Konecki U, Woo LSC. 1992. Tissue- and development-specific expression of the human phenylalanine hydroxylase/chloramphenicol acetyltransferase fusion gene in transgenic mice. J Biol Chem 267:1510515110.
  • Waters PJ, Parniak MA, Hewson AS, Scriver CR. 1998. Alterations in protein aggregation and degradation due to mild and severe missense mutations (A104D, R157N) in the human phenylalanine hydroxylase gene (PAH). Hum Mutat 12:344354.
  • Waters PJ, Parniak MA, Akerman BR, Jones AO, Scriver CR. 1999. Missense mutations in the phenylalanine hydroxylase gene (PAH) can cause accelerated proteolytic turnover of PAH enzyme: a mechanism underlying phenylketonuria. J Inher Metab Dis 22:208212.
  • Weglage J, Moller HE, Wiedermann D, Cipcic-Schmidt S, Zschocke J, Ullrich K. 1998a. In vivo NMR spectroscopy in patients with phenylketonuria. Clinical significance of interindividual differences in brain phenylalanine concentrations. J Inherit Metab Dis 21:8183.
  • Weglage J, Wiedermann D, Moller H, Ullrich K. 1998b. Pathogenesis of different clinical outcomes in spite of identical genotypes and comparable blood phenylalanine concentration in phenylketonuria. J Inher Metab Dis 21:181182.
  • Weglage J, Pietsch M, Feldmann R, Koch H-G, Zschocke J, Hoffman G, Muntau-Heger A, Denecke J, Guldberg P, Guttler F, Moller H, Wendel U, Ullrich K, Harms E. 2001. Normal clinical outcome in untreated subjects with mild hyperphenylalaninemia. Pediatr Res 49:532536.
  • Weiss KM, Buchanan AV. 2003. Evolution by phenotype: a biomedical perspective. Perspect Biol Med 46:159182.
  • Weiss KM. 2004. Cryptic causation of human disease: reading between the (germ) lines. Trends Genet 21:8288.
  • Wollaston WH. 1810. On cystic oxide, a new species of urinary calculus. Philos Trans R Soc Lond 100:223230.
  • Woo SLC, Lidsky AS, Güttler F, Chandra T, Robson KJH. 1983. Cloned human phenylalanine hydroxylase gene allows prenatal diagnosis and carrier detection of classical phenylketonuria. Nature 306:151155.
  • Woolf LI, Griffiths R, Moncrieff A. 1955. Treatment of phenylketonuria with a diet low in phenylalanine. Br Med J 1:57.
  • Woolf LI, McBea MS, Woolf FM, Calahane SF. 1975. Phenylketonuria as a balanced polymorphism: the nature of the heterozygote advantage. Ann Hum Genet 38:461469.
  • Zschocke J. 2003. Phenylketonuria mutations in Europe. Hum Mutat 21:345356.